BMS delays Alzheimer’s psychosis phase 3 readout despite strong earnings
What happened
Bristol Myers Squibb postponed the phase 3 data readout for its Alzheimer’s psychosis drug Cobenfy from 2026 to early 2027, spreading the releases across the year. This delay occurred even as BMS beat quarterly revenue estimates and raised its full-year guidance, signaling confidence in its broader portfolio.













